Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2930 vs Trastuzumab in HER2-Positive Advanced Breast Cancer
NCT07047365Phase 3Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2930 injection + oxaliplatin + capecitabine + bevacizumab in breast cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Jul 2025; status: recruiting.
02
Drugs
TQB2930 injection + oxaliplatin + capecitabine + bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07047365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047365.